1. Natalizumab-associated reversible encephalopathy syndrome mimicking progressive multifocal leukoencephalopathy.
- Author
-
Décard BF, Haghikia A, Tönnes C, Thöne J, Lukas C, Chan A, and Gold R
- Subjects
- Adult, Antibodies, Monoclonal, Humanized therapeutic use, Anticonvulsants therapeutic use, Brain pathology, Glatiramer Acetate, Humans, Immunosuppressive Agents therapeutic use, Magnetic Resonance Imaging, Male, Multiple Sclerosis, Chronic Progressive drug therapy, Natalizumab, Peptides therapeutic use, Psychomotor Agitation complications, Seizures chemically induced, Seizures drug therapy, Spinal Cord pathology, Antibodies, Monoclonal, Humanized adverse effects, Brain Diseases chemically induced, Brain Diseases diagnosis, Leukoencephalopathy, Progressive Multifocal chemically induced, Leukoencephalopathy, Progressive Multifocal diagnosis, Multiple Sclerosis, Chronic Progressive complications
- Abstract
Progressive multifocal leukoencephalopathy is a rare but potentially lethal adverse event in natalizumab treated multiple sclerosis patients. We report on a 40-year old Caucasian man with typical relapsing progressive multiple sclerosis, who developed a reversible leukoencephalopathy syndrome after 43 natalizumab infusions mimicking progressive multifocal leukoencephalopathy. To our knowledge, this is the first case of its kind. Our case suggests that awareness ought to be sharpened for reversible leukoencephalopathy syndrome in the follow-up of natalizumab treated multiple sclerosis patients.
- Published
- 2013
- Full Text
- View/download PDF